Insider buying last 90 days
No open-market insider purchases were filed for GDRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GDRX insider filing, plotted on the chart in Gekko.Open GDRX in Gekko
NASDAQ: GDRX
GoodRx (GDRX) Stock Analysis & Forecast
Oct 12 close
$3.48+0.05 (+1.5%)
Gekko Brief
AI summaryOct 12 closeGoodRx trades at $3.48, up 1.5% on the day, sitting just above both its 50-day average of $3.46 and its 200-day average of $2.77, with the shorter average above the longer one. The stock has climbed 15.6% over three months and 61.9% over six months, though it remains down 25% over the past year, within a 52-week range of $1.77 to $4.72. The GekkoIndex reads 54.4, placing GDRX in the Neutral zone, down 6 points over the last five readings. Gekko Fair Value stands at $4.25, putting the current price 18.1% below that mark.
Over the next 20 trading days, the main event is the earnings report scheduled for 3 November 2026, 21 days out, which falls inside a typical holding window for swing positions. The prior quarter saw GoodRx beat its EPS estimate of $0.08, with the stock reacting 11.4% afterward; average absolute moves around results have run 10.3%. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Analyst coverage from 10 firms splits 4 buy, 4 hold and 2 sell, with a consensus target of $3.95, implying 13.5% upside from current levels. Seasonality is mixed: over five years, the next 20 trading days from this point averaged a 5.2% decline, rising in 3 of those years, a pattern worth noting given the proximity of earnings.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
GoodRx price vs fair value
Close $3.48200-day averageGekko Fair Value $4.25
GoodRx quick facts
- Market cap
- $1.21B
- P/E ratio
- 67.2
- Forward P/E
- 10.3
- EPS, TTM
- $0.05
- Revenue, TTM
- $785.2M
- Profit margin
- 2.1%
- Dividend yield
- —
- Beta
- 1.69
- Volume
- 814,785 avg 786,019
- 1-year return
- −25.0%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±9.6%
- 50-day average
- $3.46
- 200-day average
- $2.77
- Next earnings
- Nov 3
- Shares outstanding
- 107.2M
GoodRx swing-trade checklist
GoodRx scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $3.48 is above the 50-day ($3.46) and 200-day ($2.77) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54.4, Neutral
Reading 54.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
18.1% below
Price is 18.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−5.2% on average
From this point in the calendar, the next 20 trading days averaged −5.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
GoodRx stock chart and price history
GoodRx closed at $3.48 on Oct 12, 2026, −25.0% over the past year, inside a 52-week range of $1.77 to $4.72.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.7%
- 3 months
- +15.6%
- 6 months
- +61.9%
- 1 year
- −25.0%
The full GDRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GDRX in Gekko
Follow GoodRx through every session
Put GDRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GDRX in GekkoFree for 7 days. No credit card required.
About GoodRx
GoodRx gives people across the United States a way to check and reduce what they pay for prescription drugs. Through its digital platform, consumers can compare medication prices by location and find discounts, including through exclusive GoodRx codes that can be applied at pharmacies nationwide to bring costs down.
Beyond price comparison, GoodRx offers subscription plans, telehealth services, and programs built for pharmaceutical manufacturers. It also works with pharmacy benefit managers, the organizations that manage drug formularies and handle the pricing that connects consumers, pharmacies, and payers for prescription transactions.
GoodRx was founded in 2015 and is headquartered in Santa Monica, California. Its shares are listed on the NASDAQ under the ticker GDRX.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- goodrx.com
GoodRx GekkoIndex: the smart money zone
GoodRx’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.4, in the Neutral zone, down 6 points over five sessions.
54.4Neutral
Down 6 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 60 | +2.2% | +2.0% | ||
| Accumulation | 251 | −0.1% | −1.3% | ||
| Neutral (current zone) | 341 | −0.2% | −0.9% | ||
| Distribution | 21 | −5.3% | −4.9% | ||
| Selling | 9 | Too few readings yet | |||
Average GDRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the GDRX price, zone by zone.Track GDRX in Gekko
Is GoodRx stock overvalued? Gekko Fair Value
GoodRx trades 18.1% below Gekko Fair Value of $4.25, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what GoodRx shares are worth, recalculated every trading day.
$4.25
Gekko Fair Value, Oct 10, 2026
18.1% Undervalued
At the end of Aug 2026 the price was 21.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open GDRX in Gekko
GoodRx insider and Congress trading
No open-market insider purchases were filed for GoodRx, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GDRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GDRX, plotted on the chart in Gekko.Open GDRX in Gekko
Buybacks
GoodRx has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.95M
- As a share of market cap
- 0.16%
- Trailing four quarters
- $85.00M
From company filings.
GoodRx earnings: next date and track record
GoodRx reports on Nov 3, 2026 (22 days away), and beat the EPS estimate in 1 of its last 8 reports.
Next earnings report
Nov 3, 2026
22 days away
- EPS estimate
- $0.08
- Revenue estimate
- $201.9M
1 of 8reports beat the EPS estimate
±10.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- GoodRx exceeded Q2 2026 revenue expectations with strong performance driven by Pharma Direct scaling and subscription growth. GLP-1 access and manufacturer adoption of consumer direct pricing programs were key drivers. The company launched GoodRx Companion in May and sees 280 million annual platform visits. A CFO transition occurred, with Justin Fengler replacing Chris McGinnis effective immediately.
- Guidance
- Management is raising full year 2026 revenue and adjusted EBITDA outlook based on first-half performance. The company expects to return to year-over-year revenue growth earlier than previously anticipated, signaling improved business durability.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.08 est $0.08 | $200.4M est $193.2M | +11.4% |
| May 6, 2026 | $0.07 est $0.07 | $194.0M est $185.4M | +10.9% |
| Feb 25, 2026 | $0.09 est $0.09 | $194.8M est $193.3M | −16.0% |
| Nov 4, 2025 | $0.08 est $0.09 | $196.0M est $193.3M | +0.6% |
| Aug 6, 2025 | $0.09 est $0.10 | $203.1M est $205.3M | −21.0% |
| May 7, 2025 | $0.09 est $0.09 | $203.0M est $202.2M | −0.5% |
| Feb 27, 2025 | $0.09 est $0.10 | $198.6M est $199.7M | +1.8% |
| Nov 7, 2024 | $0.08 est $0.09 | $195.3M est $200.2M | −20.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
GoodRx stock forecast and analyst price targets
Analysts’ average 12-month price target for GoodRx is $3.95, +13.5% from the last close, from 10 firms rating the stock in the last 90 days.
$3.95consensus 12-month target, +13.5% from the last close
Now $3.48Avg $3.95
Low $2.65High $5
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | Bank of America Securities | $2.65 | −23.9% |
| Aug 25 | Bank of America Securities | $2.65 | −23.9% |
| Aug 20 | Barclays | $4 | +14.9% |
| Aug 14 | Truist Financial | — | — |
| Aug 13 | UBS | $3.75 | +7.8% |
−0.9%average 20-day move after past Neutral readings
−5.2%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
GoodRx seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, GoodRx averaged −5.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.4% | 2 of 5 |
| Next 10 trading days | −1.0% | 2 of 5 |
| Next 15 trading days | −3.9% | 2 of 5 |
| Next 20 trading days | −5.2% | 3 of 5 |
| Next 30 trading days | −17.3% | 1 of 5 |
For scale, GDRX’s typical 20-trading-day move in either direction is about 9.6%.
GoodRx market cap and key statistics
GoodRx’s market cap is $1.21B, with a P/E ratio of 67.2 and revenue of $785.2M over the last twelve months.
Valuation
- Market cap
- $1.21B
- P/E ratio
- 67.2
- Forward P/E
- 10.3
- EPS, TTM
- $0.05
- Gekko Fair Value
- $4.25
Trading
- Volume
- 814,785
- Avg volume, 20 days
- 786,019
- 52-week high
- $4.72
- 52-week low
- $1.77
- Shares outstanding
- 107.2M
Financials
- Revenue, TTM
- $785.2M
- Profit margin
- 2.1%
- Return on equity
- 2.5%
- Quarterly earnings growth, YoY
- −44.5%
Risk and income
- Beta
- 1.69
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±9.6%
GoodRx peers
GoodRx’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
GoodRx stock FAQ
What is GoodRx’s market cap?
GoodRx’s market cap is $1.21B at the Oct 12, 2026 close of $3.48, with 107.2M shares outstanding. The shares trade on a P/E ratio of 67.2.
What is the GoodRx stock forecast?
The consensus analyst 12-month price target for GoodRx is $3.95, +13.5% from the last close. Of the 10 firms that rated the stock in the last 90 days, 4 rate it a buy, 4 a hold and 2 a sell. Gekko doesn’t publish price predictions of its own.
Is GoodRx stock overvalued or undervalued?
On Gekko’s estimate GoodRx is undervalued: the Oct 12, 2026 close of $3.48 is 18.1% below Gekko Fair Value of $4.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does GoodRx report earnings next?
GoodRx is expected to report on Nov 3, 2026 (22 days away). Analysts expect earnings of $0.08 per share on revenue of $201.9M. GoodRx beat the earnings estimate in 1 of its last 8 reports, moving 10.3% on average across the report.
What is GoodRx’s 52-week high and low?
GoodRx’s 52-week high is $4.72 and its 52-week low is $1.77; it closed at $3.48 on Oct 12, 2026, −25.0% over the past year. Over the last five years the shares peaked at $47.54 on Oct 21, 2021.
Is GoodRx stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See GoodRx the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.